Ken Griffin Bio Line Rx Ltd. Transaction History
Citadel Advisors LLC
- $505 Billion
- Q3 2024
A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Bio Line Rx Ltd. stock. As of the latest transaction made, Citadel Advisors LLC holds 46,500 shares of BLRX stock, worth $22,320. This represents 0.0% of its overall portfolio holdings.
Number of Shares
46,500
Previous 49,900
6.81%
Holding current value
$22,320
Previous $28,000
10.71%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding BLRX
# of Institutions
37Shares Held
3.3MCall Options Held
46.5KPut Options Held
6.3K-
Alyeska Investment Group, L.P. Chicago, IL866KShares$415,9170.0% of portfolio
-
Cvi Holdings, LLC Wilmington, DE816KShares$391,5274.05% of portfolio
-
Envestnet Asset Management Inc239KShares$114,8090.0% of portfolio
-
Morgan Stanley New York, NY198KShares$94,8170.0% of portfolio
-
Values First Advisors, Inc.198KShares$94,8070.06% of portfolio
About BioLineRx Ltd.
- Ticker BLRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,524,500
- Market Cap $29.5M
- Description
- BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. The company develops Motixafortide, a peptide, which has completed Phase 3 clinical trials for the treatment of autologous stem cell mobilization and Phase 2a clinical trials for the treatment of pancreatic cancer; and that is in Phase 2 clinical trials ...